Ann: Investor Presentation, page-393

Cynata Therapeutics Limited (ASX:CYP)

Cynata Therapeutics shares were up 59.5% in May, with shares up 148.1% over the 12-months to 31 May 2024.

Cynata Therapeutics is a clinical-stage biotechnology company specialising in cell therapeutics. The company has three active clinical trials across multiple therapeutic areas including Acute graft versus host disease (aGvHD), Diabetic Foot Ulcer (DFU) and osteoarthritis. The company is expecting a number of readouts from these trials over the next two years.

The most advanced clinical trial is the Phase 3 trial of CYP-004 for the treatment of osteoarthritis. This trial is well advanced with patient recruitment complete.

The trial is a randomised and placebo-controlled with the primary endpoints being: (i) the proportion of patients achieving patient-acceptable symptom state (PASS) for knee pain at 24 months; and (ii) central medial femorotibial (cMFT) cartilage thickness change from baseline to 24 months. A total of 321 patients were enrolled and will be followed up for two years. With enrolment completed in November 2023